Cargando…

Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis

COVID-19 vaccines are safe for people living with MS on or off disease-modifying therapies and are important for the prevention of COVID-19. Antibody responses for individuals on certain DMTs may be diminished, however, T-cell responses may be preserved in those individuals. Data are lacking regardi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Robert K., Rammohan, Kottil W., Williams, Mitzi J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336531/ https://www.ncbi.nlm.nih.gov/pubmed/34347280 http://dx.doi.org/10.1007/s40120-021-00266-z

Ejemplares similares

Cerebrospinal fluid in multiple sclerosis
por: Rammohan, Kottil W.
Publicado: (2009)

Multiple sclerosis: As we see it today and glimpses of tomorrow
por: Rammohan, Kottil W.
Publicado: (2009)

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
por: Delgado, Silvia, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
por: Garg, Neeta, et al.
Publicado: (2022)

Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era
por: Nicholas, Jacqueline A., et al.
Publicado: (2021)

An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion
por: Alroughani, Raed, et al.
Publicado: (2019)

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
por: Rammohan, Kottil, et al.
Publicado: (2020)

Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab
por: Flores-Gonzalez, Ramon E, et al.
Publicado: (2021)

Tolerogenic vaccines for Multiple Sclerosis
por: Mannie, Mark D., et al.
Publicado: (2013)

Lifestyle, Exercise and Activity Package for People living with Progressive Multiple Sclerosis (LEAP-MS): adaptions during the COVID-19 pandemic and remote delivery for improved efficiency
por: Lowe, Rachel, et al.
Publicado: (2021)

Living with Systemic Sclerosis: A Patient and Physician Perspective
por: Young, Arissa, et al.
Publicado: (2023)

Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19
por: Shin, Robert K., et al.
Publicado: (2022)

COVID‐19 Vaccine Response in People with Multiple Sclerosis
por: Tallantyre, Emma C., et al.
Publicado: (2021)

What Is the True Impact of Cognitive Impairment for People Living with Multiple Sclerosis? A Commentary of Symposium Discussions at the 2020 European Charcot Foundation
por: Morrow, Sarah A., et al.
Publicado: (2023)

Personalizing Medicine and Technologies to Address the Experiences and Needs of People with Multiple Sclerosis
por: Henschke, Adam, et al.
Publicado: (2021)

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study
por: Comi, Giancarlo, et al.
Publicado: (2018)

COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile
por: Ciampi, Ethel, et al.
Publicado: (2020)

COVID-19 vaccination willingness among people with multiple sclerosis
por: Xiang, Xinran M, et al.
Publicado: (2021)

COVID-19 Vaccination in People with Multiple Sclerosis. the Kuwait Experience
por: Alroughani, Raed, et al.
Publicado: (2022)

Making COVID-19 vaccinations accessible for people with disabilities
por: Rotenberg, Sara, et al.
Publicado: (2021)

People at heightened risk of deterioration from COVID-19: living ‘with’ or living ‘despite’ public health communications?
por: Ryan, Rebecca, et al.
Publicado: (2023)

Expert Perspectives on the Vaccination of Individuals Who Are at Increased Risk of Meningococcal Disease Due to Medical Conditions: A Podcast
por: Herrera-Restrepo, Oscar, et al.
Publicado: (2023)

Longitudinal Study of Retinal Structure, Vascular, and Neuronal Function in Patients With Relapsing-Remitting Multiple Sclerosis: 1-Year Follow-Up
por: Chen, Qi, et al.
Publicado: (2021)

Fairer financing of vaccines in a world living with COVID-19
por: Megiddo, Itamar, et al.
Publicado: (2020)

Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
por: Mao, Zhifeng, et al.
Publicado: (2018)

Are vaccines against COVID-19 tailored to the most vulnerable people?
por: Antonelli Incalzi, Raffaele, et al.
Publicado: (2021)

Ensuring Equitable COVID-19 Vaccination for People With Disabilities and Their Caregivers
por: Wiggins, Lisa D., et al.
Publicado: (2021)

Focusing COVID-19 vaccinations on elderly and high-risk people
por: Brenner, Hermann
Publicado: (2021)

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
por: Giovannoni, Gavin, et al.
Publicado: (2018)

Family Planning for People with Multiple Sclerosis in Saudi Arabia: an Expert Consensus
por: Al Jumah, Mohammed, et al.
Publicado: (2021)

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2021)

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis
por: Tallantyre, Emma C, et al.
Publicado: (2022)

COVID-19 vaccination in people with multiple sclerosis, real-life experience
por: Alroughani, Raed, et al.
Publicado: (2022)

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2022)

COVID-19 vaccine hesitancy among Italian people with multiple sclerosis
por: Proietti, Francesca, et al.
Publicado: (2022)

COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece
por: Bakirtzis, Christos, et al.
Publicado: (2023)

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
por: Filippi, Massimo, et al.
Publicado: (2021)

The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients
por: Kloc, Malgorzata, et al.
Publicado: (2020)

Adapting Cancer Civil Society Organizations to Accelerate COVID-19 Vaccinations in People Living With Cancer in Low- and Middle-Income Countries—A Commentary
por: Munisamy, Murallitharan, et al.
Publicado: (2021)

Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory Medicine
por: Kantor, Daniel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o01runkm5h4p2ftjavomattvn2